First published at 14:32 UTC on June 3rd, 2022.
"What we identified is that the cannabinoids for inflammation controlling the primary cytokine pathways in the human body - cannabinoids have almost no therapeutic effects compared to JUVA 19 or JUVA 41."
"When we combined any othe…
MORE
"What we identified is that the cannabinoids for inflammation controlling the primary cytokine pathways in the human body - cannabinoids have almost no therapeutic effects compared to JUVA 19 or JUVA 41."
"When we combined any other cannabinoid - THC, CBD - the combination of flavonoids and what we would know as the entourage effect with any of our JUVA 41 or JUVA 19, it down-regulated their potency and activity, full stop!" ~Doug Chloupek, the CEO and Founder of Juva Life
Doug Chloupek, the CEO and Founder of Juva Life (OTCQB: JUVAF) - Juva Life is a cannabis cultivation and life sciences company aimed of unlocking the secret of pain management, and has navigated the complex financial regulatory system in order to make Juva a publicly traded company in the USA, Canada, and Germany, collectively raising $38 Million to-date.
Episode 965 The #TalkingHedge interviews Doug Chloupek, CEO & Founder at Juva Life...
https://youtu.be/gy8MPyPXV0Q
LESS